“Pulmonary Arterial Hypertension-Pipeline Insights, 2015”- A DelveInsight’s Report

NEW DELHI - Aug. 13, 2015 - PRLog -- The Pulmonary Arterial Hypertension-Pipeline Insights, 2015 report provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

·     The report gives information of 40+ pipeline drugs with 35+ companies actively involved in drug development. There are 5 drugs which are in phase III, 13 in phase II, 4 in phase I, 20 in pre-clinical and 2 in discovery.

·     R&D activities and technologies used along with the pipeline molecules in development.

·  Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

·  Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Pulmonary Arterial Hypertension-Pipeline Insights, 2015report provides Pulmonary Arterial Hypertension Landscape across the globe. Therefore the report on Pulmonary Arterial Hypertension -Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.